Tango Therapeutics Exec Chair Barbara Weber departs; severance, equity acceleration disclosed

Tango Therapeutics, Inc.

Dr. Barbara Weber stepped down as Executive Chair and board member effective Aug 3, 2026; separation agreement executed Aug 6, 2026.
Severance: base salary through Dec 31, 2026; COBRA reimbursement to Dec 31, 2026.
Full acceleration of outstanding options and RSUs, subject to Compensation Committee approval; exercise period extended to Aug 3, 2027 or original expiry.
Pro-rata 2026 annual incentive compensation paid by Mar 15, 2027, based on company and individual performance.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.